Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05226078). This is a study registration, not published results. Lead sponsor: Abramson Cancer Center at Penn Medicine. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 64 participants (ACTUAL). Conditions: Chronic Insomnia, Cancer-related Problem/Condition, Cancer-Related Syndrome. Interventions: BEHAVIORAL: Cognitive Behavioral Therapy for Insomnia. Primary outcome measures: Recruitment , Baseline to End of Treatment (Up to 12 weeks); Adherence , Baseline to End of Treatment (Up to 12 weeks); Treatment Acceptability , End of Treatment; Retention , Baseline to End of Treatment (Up to 12 weeks). Brief summary: Cancer-related fatigue (CRF) and insomnia are prevalent among cancer patients and have been linked to de-creases in quality of life and poorer overall survivorship. Currently, the mechanisms underlying CRF are not well understood, which has led to treatments that are only moderately effective. In addition, when compared to CBT-I in the general population, the treatment outcomes in CBT-I with cancer patients are subpar and, as such, this study will evaluate whether dose of CBT-I is effective in ameliorating CRF.